AIM News and Press, AIM ImmunoTech Inc. From 08/30/22

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: America...

AIM ImmunoTech ( NYSE: AIM ) on Thursday said it had commenced its phase 2 study of cancer treatment Ampligen for pancreatic cancer after getting an approval for the trial protocol from an Institutional Review Board (IRB). "Receiving IRB approval for our Phase 2 study of A...

Company receives IRB approval of study protocol Ampligen ® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA, Fla., Aug. 18, 2022 (GLOBE NEW...

Court Orders AIM Not to Hold Annual Meeting Prior to October 31, 2022 Delaware Court Preliminary Injunction Hearing Scheduled for October 5, 2022 NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM&#...

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement ...

– On track to commence Phase 2 study for lead program evaluating Ampligen ® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones ȁ...

Immuno-pharma company AIM ImmunoTech ( NYSE: AIM ) announced plans to seek FDA clearance to study its experimental long COVID therapy Ampligen on Thursdasy after the company reported preliminary pilot study data for the candidate. AIM ImmunoTech ( AIM ) generated data ...

OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral ...

NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “A...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off Thursday with an overview of the biggest pre-market stock movers traders need to know about! We’ve got bankruptcy talk, takeover rumors, updated out...